Scope: Vitamin E (VE) analogues, epitomised by the prototypic a-tocopheryl succinate (a-TOS), are potent anti-cancer agents. a-TOS has recently been shown to trigger apoptosis by targeting the ubiquinone (UbQ) binding site(s) of the mitochondrial complex II (CII) and to cause excessive production of reactive oxygen species. Methods and results: We have modelled, using two approaches, a range of VE analogues into the proximal UbQ (Qp) binding site of CII. This study reveals that in both cases, the calculated interaction energies of individual VE analogues correlate (R2 value 40.8) with their toxicity to cancer cells. Conclusion: These data further support the UbQ site(s) of CII as an important target determining the anti-cancer activity of VE analogues as well as other emerging anti-cancer drugs.